View source for 6tvu


==Structure of native gp41 derived peptide fusion inhibitor==
<StructureSection load='6tvu' size='340' side='right'caption='[[6tvu]], [[Resolution|resolution]] 1.25&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[6tvu]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TVU OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6TVU FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.25&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=NH2:AMINO+GROUP'>NH2</scene>, <scene name='pdbligand=OBF:(2S)-2-AMINO-4,4-DIFLUOROBUTANOIC+ACID'>OBF</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6tvu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tvu OCA], [https://pdbe.org/6tvu PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6tvu RCSB], [https://www.ebi.ac.uk/pdbsum/6tvu PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6tvu ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/Q5VGF0_9HIV1 Q5VGF0_9HIV1] 
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
With the emergence of novel viruses, the development of new antivirals is more urgent than ever. A key step in human immunodeficiency virus type 1 (HIV-1) infection is six-helix bundle formation within the envelope protein subunit gp41. Selective disruption of bundle formation by peptides has been shown to be effective; however, these drugs, exemplified by T20, are prone to rapid clearance from the patient. The incorporation of non-natural amino acids is known to improve these pharmacokinetic properties. Here, we evaluate a peptide inhibitor in which a critical Ile residue is replaced by fluorinated analogues. We characterized the influence of the fluorinated analogues on the biophysical properties of the peptide. Furthermore, we show that the fluorinated peptides can block HIV-1 infection of target cells at nanomolar levels. These findings demonstrate that fluorinated amino acids are appropriate tools for the development of novel peptide therapeutics.

Systematic Evaluation of Fluorination as Modification for Peptide-Based Fusion Inhibitors against HIV-1 Infection.,Huhmann S, Nyakatura EK, Rohrhofer A, Moschner J, Schmidt B, Eichler J, Roth C, Koksch B Chembiochem. 2021 Dec 10;22(24):3443-3451. doi: 10.1002/cbic.202100417. Epub 2021 , Oct 22. PMID:34605595<ref>PMID:34605595</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 6tvu" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Human immunodeficiency virus 1]]
[[Category: Large Structures]]
[[Category: Eichler J]]
[[Category: Huhmann S]]
[[Category: Koksch B]]
[[Category: Moschner J]]
[[Category: Nyakatura EK]]
[[Category: Rohrhofer A]]
[[Category: Roth C]]
[[Category: Schmidt B]]